Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | RBP4 | P02753 | 5/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22482202 | 0.79 | NPC1 (0.45) | NPC1RAB9ARBP4CDK5GAA | |
| SCHEMBL22482253 | 0.78 | GSK3B (0.41) | NPC1RAB9ARBP4CDK5GAA | |
| SCHEMBL4762236 | 0.74 | GAA (0.41) | NPC1RAB9ARBP4GAAHCAR2 | |
| SCHEMBL5263474 | 0.74 | HCAR2 (0.61) | RBP4HCAR2KMT2A | |
| Trifluoroacetic Acid SCHEMBL29915603 | 0.73 | RBP4 (0.38) | RBP4HCAR2KMT2A | |
| Hydrochloric Acid SCHEMBL22615346 | 0.72 | HCAR2 (0.59) | RBP4HCAR2KMT2A | |
| SCHEMBL30226131 | 0.71 | NPC1 (0.51) | NPC1RAB9ACDK5GAAHCAR2 | |
| SCHEMBL4778041 | 0.71 | NPC1 (0.60) | NPC1RAB9ACDK2GAACRHR1 | |
| SCHEMBL22482116 | 0.71 | RBP4 (0.39) | NPC1RAB9ARBP4GAAHCAR2 | |
| SCHEMBL4870401 | 0.70 | NPC1 (0.55) | NPC1RAB9ARBP4RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099175-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2009-04-16 | — | — | US | disclosed |
| EP-1991530-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1991531-A1 | CINNOLINE AND QUINOXALINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1989195-A1 | PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007103260-A1 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007100880-A1 | CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099175-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | NPC1 1921/4885RAB9A 533/4885RBP4 3573/4885 |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | NPC1 1992/4885RAB9A 440/4885RBP4 3264/4885 |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | NPC1 2050/4885RAB9A 593/4885RBP4 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.